English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduA new pathology tool created at Yale harnesses barcode technology and shows potential for use in cancer diagnoses. The technology, Patho-DBiT (pathology-compatible deterministic barcoding in tissue), was discussed in a new study that published Sept. 30 in the journal Cell. Co-corresponding author Dr. Mina Xu, a Yale Cancer Center (YCC) member, professor of pathology at Yale School of Medicine (YSM), and the YSM director of hematopathology, shared her enthusiasm for the new tool.
Tag: Tumor Biology
Kidney cancer treatments and tumor biology can activate different immune-modifying processes in patients
The findings out of Dana-Farber Cancer Institute highlight that the mechanisms of immune modulation are different in patients treated with immunotherapy and anti-angiogenic combinations. The results also point to the role of tumor biology in the diversity and actions of tumor-infiltrating immune cells brought into action by these treatments. The findings might be important for predicting or understanding treatment outcomes in advanced kidney cancer.
Cell competition may explain cancer relapses, UT Southwestern research suggests
A normal process called cell competition, in which healthy tissues eliminate unhealthy cells, could be responsible for cancer relapses in patients months or years after they were declared cancer-free